WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 406789
Description: NVP-LCQ195; also known as LCQ 195 and AT9311, is a potent inhibitor of cyclin-dependent kinases (CDKs). LCQ195 inhibits CDK1, CDK2 and CDK5, as well as CDK3 and CDK9. LCQ195 induced cell cycle arrest and eventual apoptotic cell death of MM cells, even at sub-μmol/l concentrations, spared non-malignant cells, and overcame the protection conferred to MM cells by stroma or cytokines of the bone marrow milieu. Cell cycle regulators, such as cyclin-dependent kinases (CDKs), are appealing targets for multiple myeloma (MM) therapy given the increased proliferative rates of tumour cells in advanced versus early stages of MM.
MedKoo Cat#: 406789
Chemical Formula: C17H19Cl2N5O4S
Exact Mass: 459.0535
Molecular Weight: 460.33
Elemental Analysis: C, 44.36; H, 4.16; Cl, 15.40; N, 15.21; O, 13.90; S, 6.96
Synonym: NVP-LCQ-195; NVP-LCQ 195; NVP-LCQ195. LCQ-195; LCQ 195; LCQ195; AT9311; AT-9311; AT 9311.
IUPAC/Chemical Name: 4-[(2,6-dichlorobenzoyl)amino]-N-(1-methylsulfonylpiperidin-4-yl)-1H-pyrazole-5-carboxamide
InChi Key: CCUXEBOOTMDSAM-UHFFFAOYSA-N
InChi Code: InChI=1S/C17H19Cl2N5O4S/c1-29(27,28)24-7-5-10(6-8-24)21-17(26)15-13(9-20-23-15)22-16(25)14-11(18)3-2-4-12(14)19/h2-4,9-10H,5-8H2,1H3,(H,20,23)(H,21,26)(H,22,25)
SMILES Code: O=C(C1=C(NC(C2=C(Cl)C=CC=C2Cl)=O)C=NN1)NC3CCN(S(=O)(C)=O)CC3
1: McMillin DW, Delmore J, Negri J, Buon L, Jacobs HM, Laubach J, Jakubikova J,
Ooi M, Hayden P, Schlossman R, Munshi NC, Lengauer C, Richardson PG, Anderson KC,
Mitsiades CS. Molecular and cellular effects of multi-targeted cyclin-dependent
kinase inhibition in myeloma: biological and clinical implications. Br J
Haematol. 2011 Feb;152(4):420-32. doi: 10.1111/j.1365-2141.2010.08427.x. Epub
2011 Jan 11. PubMed PMID: 21223249; PubMed Central PMCID: PMC4042406.